Transition Year Playbook: Keeping Your Prescription Drug Plans Creditable in 2025–2026

Introduction

Change is in the air. As CMS pushes forward with updates to Medicare Part D rules, employer-sponsor plans are entering a delicate “transition zone.” 2025 still allows the old simplified method, while 2026 brings a higher actuarial threshold. That means plans that currently pass may not in future years - unless you act now.

Let’s walk through a playbook for surviving (and thriving) during the transition.

1. Understand the 2025 vs. 2026 Methods

  • 2025: Many non-RDS plans can still use the existing simplified method (60% of drug costs).

  • 2026: CMS is mandating a jump to 72% of drug costs, expanding requirements (e.g. biologics, removing benefit maximums) to align with enhancements under the Inflation Reduction Act. Risk Strategies+2vitacompanies.com+2

  • For 2026 only, non-RDS plans may choose either method, giving you flexibility (if your plan passes under both). Risk Strategies+1

2. Identify At-Risk Plan Designs

Not every plan will survive the transition. Those at greatest risk include:

  • High deductible or high cost-sharing designs

  • Plans barely exceeding the 60% threshold today

  • Sparse formularies, especially excluding biologics

  • Plans with limited pharmacy networks

If your plan fits any of those, start adjusting now.

3. Use Technology to Stay Agile

Manual testing or outsourcing for each year gets painful fast. You need a tool that adapts as rules change. Creditable allows you to:

  • Instantly test plan designs month over month

  • Generate defensible reports you can reuse

  • Re-run tests if design changes mid-year

  • Stay responsive in a shifting regulatory environment

5. What to Watch in Late 2026 & Beyond

  • 2027 may eliminate the old simplified method entirely, making 72% or actuarial testing mandatory

  • New CMS clarifications may tighten “reasonable access” definitions

  • Industry pressure to standardize testing tools may rise

If you build a disciplined, transparent approach now, you’ll be best positioned to ride the changes rather than fight them.

Conclusion / Call to Action

The 2025–2026 transition is your window to future-proof your plans. If you wait until renewal time, the changes may force you into scrambling, or worse, non-compliance.

Want help modeling your plans through 2026, stress testing them, or running side-by-side comparisons? Drop us a message or book a demo, and let’s get you ahead of the curve.

Next
Next

How 2026 CMS Changes Could Make Your Prescription Plan Non-Creditable and What You Can Do About It